Excalibur Management Corp buys $2,990,319 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Excalibur Management Corp scooped up 4,535 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 33,900 shares of Gilead Sciences which is valued at $2,990,319.Gilead Sciences makes up approximately 2.67% of Excalibur Management Corp’s portfolio.

Gilead Sciences opened for trading at $88.7 and hit $89.45 on the upside on Monday, eventually ending the session at $89, with a gain of 0.90% or 0.79 points. The heightened volatility saw the trading volume jump to 1,35,24,049 shares. Company has a market cap of $121,649 M.

Other Hedge Funds, Including , Community Bank N.a. boosted its stake in GILD in the latest quarter, The investment management firm added 3,490 additional shares and now holds a total of 4,475 shares of Gilead Sciences which is valued at $456,137. Gilead Sciences makes up approx 0.11% of Community Bank N.a.’s portfolio.Gibraltar Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 13,267 additional shares and now holds a total of 51,890 shares of Gilead Sciences which is valued at $5,289,148. Gilead Sciences makes up approx 6.90% of Gibraltar Capital Management’s portfolio. Blb&b Advisors added GILD to its portfolio by purchasing 2,917 company shares during the most recent quarter which is valued at $297,330. Gilead Sciences makes up approx 0.06% of Blb&b Advisors’s portfolio.

On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.